Avalglucosidase alfa clinical trials
Also written GZ402666 and Nexviazyme.
How each study uses avalglucosidase alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the avalglucosidase alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 6 Aug 2021 · NEXVIAZYME · BLA 761194 (FDA, Drugs@FDA)
- European Union
- 24 Jun 2022 · Nexviadyme · EMEA/H/C/005501 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 1
Genzyme, a Sanofi Company (7) · Iris Plug (1) · Sanofi (1) · Amicus Therapeutics (1)
Often tested with
Tested in the same studies.
Duvoglustat (1) · Alglucosidase alfa (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test avalglucosidase alfa.
- Jun 2027Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)Phase 4 · Genzyme, a Sanofi Company
Studies
Open first, then newest update. How each study uses avalglucosidase alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPDRecruitingPhase 4Genzyme, a Sanofi CompanyNCT06666413Written as Avalglucosidase alfaHow we know
- Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)Active, not recruitingPhase 4Genzyme, a Sanofi CompanyNCT05164055Written as Avalglucosidase alfa (GZ402666)How we know
- Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 YearsActive, not recruitingPhase 4Iris PlugNCT07652814Written as Avalglucosidase AlfaHow we know
- Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase AlfaActive, not recruitingPhase 3SanofiNCT04910776Written as avalglucosidase alfaHow we know
- A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase AlfaActive, not recruitingPhase 2Genzyme, a Sanofi CompanyNCT03019406Written as Avalglucosidase alfa (GZ402666)How we know
- Drug-drug Interaction StudyCompletedPhase 2Amicus TherapeuticsNCT01380743Written as rhGAAHow we know
- Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe DiseaseCompletedPhase 3Genzyme, a Sanofi CompanyNCT02782741Written as Avalglucosidase alfa (GZ402666)How we know
- Avalglucosidase Alfa Extension StudyCompletedPhase 2Genzyme, a Sanofi CompanyNCT02032524Written as Avalglucosidase AlfaHow we know
- Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.CompletedPhase 1Genzyme, a Sanofi CompanyNCT01898364Written as GZ402666How we know
- Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe DiseaseCompletedPhase 2Genzyme, a Sanofi CompanyNCT00025896Written as recombinant human acid alpha-glucosidase (rhGAA)How we know
Given beside what is tested · 1 — avalglucosidase alfa is usual care or a partner of the new treatment
Codes
What other systems call avalglucosidase alfa · ClinicalTrials.gg INT002184
- MeSH (NLM) C000731975avalglucosidase alfaOne source NLM
- UNII (FDA) EO144CP0X9AVALGLUCOSIDASE ALFAConfirmed FDA, NLM, Wikidata
- RxNorm 2565814One source FDA
- Wikidata Q107693067avalglucosidase alfaConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169795Avalglucosidase AlfaOne source FDA
- DrugBank DB16099One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731975 | avalglucosidase alfa | One source NLM |
| UNII (FDA) | EO144CP0X9 | AVALGLUCOSIDASE ALFA | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2565814 | — | One source FDA |
| Wikidata | Q107693067 | avalglucosidase alfa | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169795 | Avalglucosidase Alfa | One source FDA |
| DrugBank | DB16099 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.